Medicus Pharma Collaborates with Gorlin Syndrome Alliance for SKINJECT™ Access

Medicus Pharma Ltd ( (MDCX) ) has provided an announcement.

Medicus Pharma Ltd. has announced a strategic collaboration with the Gorlin Syndrome Alliance to advance compassionate access to SKINJECT™, an investigational precision therapy for Gorlin Syndrome patients. This partnership aims to utilize the Expanded Access IND Program to provide access to SKINJECT™ for patients with multiple, recurrent, or inoperable basal cell carcinomas, while integrating patient insights into the therapy’s development and collecting real-world data to support future regulatory filings.

The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.

Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech and life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets, particularly in the field of non-melanoma skin diseases.

Average Trading Volume: 383,104

Technical Sentiment Signal: Sell

Current Market Cap: $49.33M

For an in-depth examination of MDCX stock, go to TipRanks’ Overview page.